Vomiting and nausea remain among the most common complaints in small-animal practice. Selecting the correct antiemetic requires understanding how each drug targets the emetic pathway. This summary highlights mechanisms, indications, cautions, and practical selection points for two of the most widely used options: maropitant and ondansetron.
Ondansetron blocks 5-HT₃ receptors both centrally (chemoreceptor trigger zone and vomiting center) and peripherally on vagal afferent nerves in the GI tract. Because serotonin release plays a major role in chemotherapy-associated vomiting, viral enteritis, and other visceral inflammatory processes, ondansetron is particularly effective in these settings.
Maropitant selectively antagonizes neurokinin-1 (NK1) receptors in the CNS, preventing substance P from activating the final common emetic pathway. This gives maropitant broad efficacy against a wide range of emetic stimuli—including gastrointestinal disease, motion sickness, opioid-induced vomiting, and peri-anesthetic nausea.
| Ondansetron | Maropitant |
|---|---|
When to Consider: – Chemotherapy-induced emesis or scenarios where serotonin release is known to dominate (parvoviral enteritis, GI mucosal inflammation). – Severe ongoing nausea requiring rapid IV control; ondansetron can be dosed multiple times daily if needed. – Adjunctive therapy when multimodal antiemesis is appropriate (e.g., refractory vomiting). | When to Consider: – Routine treatment of acute vomiting in dogs and cats; it is the only widely available veterinary-labeled agent for this indication. – Prevention of perioperative nausea/vomiting, especially with opioid premedication. – Prevention of motion sickness in dogs (labeled use). – Broad-spectrum efficacy when the emetic trigger is uncertain. – Adjunctive therapy when multimodal antiemesis is appropriate (e.g., refractory vomiting). |
| When NOT to Use/Cautions: – Use caution in patients at risk for QT interval prolongation or on concurrent medications at affect cardiac conduction. – Rare interactions with serotonergic drugs are reported, though clinically uncommon. – Less effective than maropitant for motion sickness. – Extra-label in dogs/cats | When NOT to Use/Cautions: Avoid in puppies <8 weeks; early studies noted bone marrow effects in very young dogs. Use caution in hypovolemic or hypotensive patients—maropitant may exacerbate hypotension under anesthesia. Reduce dose or monitor carefully in hepatic disease due to hepatic metabolism. May mask vomiting, so use caution when GI obstruction or toxin exposure is suspected. |
Comparative Evidence and Clinical Pearls
Studies in dogs and cats demonstrate that both drugs reduce vomiting, though their relative efficacy depends on the emetic trigger. Maropitant often outperforms ondansetron for perioperative vomiting and motion sickness, while ondansetron may provide superior control for chemotherapy-associated nausea.
Pearls for Practice
- For routine vomiting and motion sickness, maropitant is typically first-line.
- For chemotherapy-related emesis or strongly serotonin-mediated vomiting, choose ondansetron or incorporate it into a multimodal plan.
- In dehydrated or obstructed patients, stabilize first; antiemetics may obscure progression of clinical signs.
- For chronic or repeated dosing, monitor liver function (maropitant) and ECG/medication interactions (ondansetron).
Summary
Maropitant (NK1 blockade) and ondansetron (5-HT₃ blockade) are complementary antiemetics. Clinicians should tailor drug choice based on the most likely emetic pathway, patient comorbidities, and desired onset or duration of action. When applied with a mechanistic approach, both agents markedly improve patient comfort and clinical outcomes.
By Erin White, PharmD
References
app.plumbs.com/drug/ufI3PM2LJIPROD?source=search&searchQuery=maropitant
app.plumbs.com/drug/HaMjUv5DhLPROD?source=search&searchQuery=ondanset
